The link between HIF-1 and EGF and the reported ability of mTOR inhibitors rapamycin and everolimus to reduce VEGF secretion in vitro and in vivo, renders mTOR inhibitors potentially effective against cancer cells resistant to EGFR inhibitors (Viloria-Petit et al, 2001; Ciardiello et al, 2004; Bianco et al, 2005). Here, VEGFA is linked to cancer.